[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 4 days · First seen · Last updated

Gilead Sciences HIV treatment developments

Overview

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo, a once-daily single-pill HIV treatment. The medication combines bictegravir and lenacapavir to assist adult patients who have suppressed viral loads but require a less complex regimen than their current multi-drug therapies. Clinical trials indicated the combination maintained viral suppression over 48 weeks.

In related developments regarding lenacapavir, an international Phase 3 trial (ISLEND-2) involving 626 adults across 14 countries found that an experimental once-weekly pill combining Merck’s islatravir and Gilead’s lenacapavir was as effective as standard daily therapy, maintaining viral suppression in nearly all participants after 48 weeks.

Entities

Bixlenvo · Gilead Sciences · FDA · Merck

Timeline

  1. 18 days ago

    [HEALTH] 2 sources
    Gilead Sciences receives FDA approval for new once-daily HIV pill

    New advancements in HIV treatment include the FDA approval of Gilead’s once-daily Bixlenvo pill and successful Phase 3 trial results for a potential once-weekly oral treatment.

  2. 22 days ago

    [HEALTH] 2 sources
    Gilead Sciences receives FDA approval for Bixlenvo HIV treatment

    The FDA has approved Gilead Sciences’ Bixlenvo, a once-daily HIV pill combining bictegravir and lenacapavir to provide a simplified treatment option for patients with drug resistance or complex medication needs

Sources

advocate.com · kormedi.com · timesnownews.com · tokenpost.kr